MedTrace Logo

Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

NCT01459081 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2013-01-16

No results posted yet for this study

Summary

The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.

Conditions

  • Influenza A Virus Infection
  • Influenza B Virus Infection

Interventions

DRUG

Zanamivir

10 mg inhaled by mouth, twice daily, for 5 days

DRUG

Placebo

inhaled by mouth, twice daily, for 5 days

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qingyu Xiu, MD · Shanghai Changzheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459081 on ClinicalTrials.gov